The clinical-stage biotech effectively conserved cash in the first quarter, thanks to cost cuts following last year's pipeline setback with experimental cancer drug glemba.
News & Analysis: Celldex Therapeutics
The clinical-stage biotech stretched out its cash in the fourth quarter by cost reductions and took the necessary moves in the following months to retain its listing on the Nasdaq stock exchange.
CLDX earnings call for the period ending December 31, 2018.
A rotten week for biotech didn't end well for Celldex.
There's nothing to get excited about with this clinical-stage biotech stock's double-digit-percentage gain.
The company's third-quarter earnings report gave investors lots to look forward to.
The biotech's spending cuts help it preserve cash to fund ongoing clinical studies that are key to its future success.
The clinical-stage biotech received a spark from excitement over the release of abstracts to be presented at a major conference.
A big loss despite a lack of news for the precommercial biotech.
A big gain on no news for this clinical-stage biotech.